Once you see the results in your own patients, from complex cataracts to ‘straightforward cases,’ it’s hard to imagine looking a patient in the eye and offering anything else.
When I say to patients ‘the Light Adjustable Lens is the most precise implant on Mother Earth and, for the first time in history, we can truly customize your implant...in your eye,’ they get it and want it.
The ability to change the shape of a lens to perfectly match the eye after healing has resulted in the most precise results I have ever seen!
RxSight’s Light Adjustable Lens is the biggest improvement in cataract surgery in my career. We can now deliver the highest level of vision to our patients, tailored to their needs.
The Light Adjustable Lens has such excellent accuracy and quality of vision. We are able to optimize our patient’s vision after the LAL is placed, after the procedure. We love the lens almost as much as our patients.
RxSight® has developed the first and only FDA-approved intraocular lens (IOL) that can be adjusted postoperatively (postop) to improve uncorrected visual acuity. The Light Adjustable Lens™ is implanted during a standard cataract procedure. However, visual outcomes are not dependent on the prediction of SIA, ELP, individual healing, or sophisticated equipment. Instead, vision optimization takes place after the Light Adjustable Lens is in its final position and the patient’s eye has healed, overcoming the limitations of preoperative (preop) and intraoperative prediction processes.
The Light Adjustable Lens is made of a special photosensitive material that absorbs ultraviolet (UV) light. Using a proprietary light treatment—the Light Delivery Device (LDD)—to produce modifications in lens curvature, the Light Adjustable Lens enables surgeons to precisely reshape the lens based on the visual correction needed to achieve the patient’s desired vision after cataract surgery.
To perform the light treatments, the patient is refracted and the refractive error is entered into the office-based LDD. The LDD delivers UV light in a precisely programmed pattern to induce a predictable change in the shape and refractive properties of the lens. Between 1 and 3 adjustments are possible, enabling a fully interactive process of designing and trialing the patient’s final vision. A subsequent lock-in exposure is delivered to the implanted Light Adjustable Lens to stabilize the lens power.
Following surgery, patients are provided with UV protective glasses to wear at all times to help protect the Light Adjustable Lens from indoor and outdoor sources of UV light. The patient may discontinue wear of the UV protective glasses 24 hours after the final light treatment has been completed.
With the Light Adjustable Lens, the preop discussion with patients focuses on cataract surgery and the adjustable IOL. You will not need to spend increasing amounts of preop chair time describing the patient’s refractive error, the various types of IOLs, the patient’s refractive options and targets, and how various IOL choices will impact quality of vision—all difficult and stressful decisions for patients.
Despite modern cataract surgery technologies, residual refractive error is still common due to variables of incision healing and the final effective lens position. Instead of relying on preop predictions or postop LASIK enhancements, the Light Adjustable Lens enables physicians to adjust the stabilized postop refraction. For the first time, patients can preview different visual outcomes and select a customized prescription after their surgery, giving them greater peace of mind.
FDA approval was based on results of a U.S. randomized, pivotal study that evaluated the safety and effectiveness of the Light Adjustable Lens and LDD compared to a commercially available monofocal lens in 600 eyes with preexisting astigmatism.¹
The Light Adjustable Lens and Light Delivery Device system are indicated for the reduction of residual astigmatism to improve uncorrected visual acuity after removal of the cataractous natural lens by phacoemulsification and implantation of the intraocular lens in the capsular bag in adult patients:
The system also reduces the likelihood of clinically significant residual spherical refractive errors.
For clinical study data, please see the FDA Summary of Safety and Effectiveness.
Please also see Important Safety Information below.
Aliso Viejo, CA 92656
We will connect with you shortly. We appreciate your interest in RxSight!
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. RxSight does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to RxSight. Click “Continue” to leave site or “Return to RxSight.com” to close this window and return to RxSight.com.